Answers are grounded in this paper and cite their sources.
Calibration of a quantitative systems pharmacology (QSP) model to population summaries need not identify its predictions under a new intervention. We formulate prediction extrema over calibration-compatible virtual populations as a generalized moment problem and implement finite-cohort linear programming with support-guided cohort expansion. The approach yields explicit alternative populations and constructive inner approximations to the identified prediction interval; it does not compute globally certified outer bounds. We apply it to a published atopic dermatitis model with 51 varying parameters and 14 state variables. Calibration targets are generated from a truncated reference distribution based on the published parameter distributions, rather than extracted from clinical trials. In the primary run, 60,400 candidate patients and 90 moment constraints admit mean week-16 EASI improvement of 62.1–94.5% under hypothetical IL-13 plus IL-22 blockade, compared with 79.5% in the reference population. The corresponding responder-rate range is 31.4–100.0%, compared with 72.5%. Under a one-sided weight cap of twice the empirical reference weights, the responder range is 58.1–86.8%. A second complete run supports the same qualitative conclusion. Wider prediction ranges constitute constructive evidence of non-identification, whereas narrow ranges found by a heuristic search cannot establish identification. This computational case study demonstrates how explicit calibration-compatible populations can reveal prediction uncertainty beyond a selected reference population. Clinical calibration, comprehensive plausibility assessment and global optimization certificates remain future work.
No takes yet. Share an insight, caveat, or question.
Eva Paunova (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: